Fig. 1. First-in-human immunoPET imaging of HIV persistence.

A schematic of PET-MR imaging workflow including tracer administration and imaging time points is shown in a. Imaging on day 6 was limited to a subset of participants to determine if meaningful information could be obtained over longer periods of time various tissues of interest. Representative 3-dimensional maximum intensity projection images (MR attenuation corrected, but without MR overlay) of ⁸⁹Zr-VRC01 uptake 6 and 72 h in a viremic (V2) and uninfected control (C3) participant are shown (b).